FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses)															
1. Name and Address of Reporting Person* ENGELHARDT DEAN				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) Executive Vice President					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/09/2007												
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City)	KK, NI II	(State)	(Zip)			Т	Sabla I - N	on-Deriv	ativa Sa	curitic	e Acqui	red, Dispose	l of or Rone	aficially Ow	ad	
1.Title of Security 2. Transaction Date			2A. Deemed Execution Date, if		e, if	3. Transa			uired of (D) 5. Amount of Owned Follo Transaction(s		Securities Beneficially wing Reported		6. Ownership Form:	Beneficial		
				(Monui/Da	ау/ 1 (ear)	Code	V A	mount	(A) or (D)		o (I		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common S per share	Stock, par	value \$0.01	01/09/2007				М	11 (1)	,247	A	(1)	192,290 (2)			D	
												e collection				1474 (9-02)
								contain	ed in th	is for	m are n	e collection ot required llid OMB co	to respond	d unless th		1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, i	4. Transact	tion	5. N of D Secu Acq or D of (I	rrants, op fumber Derivative arities uired (A) Disposed D)	containe form dis	ed in the plays a sed of, of the plays a sed of, of the plays are the pl	or Bende securion securior securion sec	m are n ently va eficially rities)	ot required alid OMB co Owned and Amount rlying es	to respond ntrol numb 8. Price of	9. Number Derivative Securities Beneficially Owned Following	of 10. Owners Form of Derivati Security Direct (11. Nature of Indirec Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, i	4. Transact	tion	5. N of D Secu Acq or D of (I	rrants, op fumber Derivative arities uired (A) Disposed D) tr. 3, 4,	containe form dis ed, Dispo otions, con 6. Date E and Expir	ed in the plays a sed of, or exercisable action Day/Year	or Bende securities at the sec	eficially rities) 7. Title of Unde	ot required alid OMB co Owned and Amount rlying es	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned	of 10. Owners Form of Derivati Security Direct (or Indir	11. Nature of Indirect Beneficia Ownershi (Instr. 4)

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
ENGELHARDT DEAN C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022			Executive Vice President				

Signatures

/s/ Dean Engelhardt	02/09/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person exercised a stock option to purchase 24,021 shares of Common Stock and paid the exercise price thereof by the surrender of 12,774 shares of Common Stock, for (1) a net gain in outstanding shares of Common Stock of 11,247 shares. The stated exercise prices of the stock options ranged from \$5.45 per share to \$12.51 per share and were first exercisable upon the grants thereof, which took place from October 1, 1998 to March 22, 2001. Each of the stock options would have expired within ten years of grant.
- (2) As of the date hereof, the Reporting Person directly beneficially owned 186,848 shares of Common Stock, 5,442 shares of Common Stock in Enzo Biochem's 401(K) Plan, and 48,365 options to purchase Common Stock, par value \$0.01 per share, which are exercisable within 60 days from the date hereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.